The drug candidates by key players, such as Immunovant Sciences (batoclimab), Novartis Pharmaceuticals (secukinumab), Viridian Therapeutics (VRDN-001), Sling Therapeutics (linsitinib), Regeneron Pharmaceuticals (aflibercept), ValenzaBio (VB421), and others under late- and mid-phase clinical development have the potential to create a significant positive shift in Graves Ophthalmopathy Market size in the upcoming years.
DelveInsight's "Graves Ophthalmopathy Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Graves Ophthalmopathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Graves Ophthalmopathy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Graves Ophthalmopathy: An Overview
Graves’ ophthalmopathy (GO), also known as thyroid-associated ophthalmopathy (TAO) and thyroid eye disease (TED), is the most frequent extrathyroidal manifestation of Graves’ disease (GD). It is an autoimmune disease in which the production of autoantibodies leads to inflammatory changes in the orbit. The autoantibodies presumably target a protein shared by both the orbit and the thyroid.
In more advanced eye disease, there may also be decreased eye movement and eyelids, incomplete eye closure with corneal ulceration, compression of the optic nerve, and rarely, loss of vision. It has been established that immunoreactivity against the thyrotropin receptor causes Graves’ Ophthalmopathy; the exact cause is unknown.
Graves’ Ophthalmopathy is divided into an early acute stage (also known as the active stage) and a late chronic stage (also known as the inactive stage) and is classified as mild, moderate-to-severe, and very severe, namely sight-threatening, and forms according to the impact of the disease on the QoL and the risk of vision loss.
Graves Ophthalmopathy Market Key Facts
-
In 2022, the market size of Graves’ Ophthalmopathy was the highest in the US among the 7MM, accounting for approximately USD 1,980 million, which is further expected to increase by 2032.
-
The total prevalent cases of Graves Ophthalmopathy in the United States were around 1,012,000 cases in 2022.
-
The US contributed to the largest prevalent population of Graves’ Ophthalmopathy, acquiring ~42% of the 7MM in 2022. Whereas Germany accounted for around 13% and Japan accounted for around 8% of the total population share, respectively, in 2022.
-
Among EU4 countries, Germany accounted for the largest number of Graves’ Ophthalmopathy cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
-
According to DelveInsight estimates, there were around 16,300 cases of acute Graves’ Ophthalmopathy and 41,900 cases of chronic Graves’ Ophthalmopathy in Japan in 2022. These cases are projected to increase during the forecasted period.
-
In the 7MM, approximately 20% of the patient share is attributed to males, whereas only 80% of females suffer from Graves’ Ophthalmopathy.
-
The diagnosis and treatment rate of Graves’ Ophthalmopathy is expected to increase in the coming years due to the increase in expected approvals of several pipeline candidates for the treatment of Graves’ Ophthalmopathy, thus leading to the increase in awareness among patients and clinicians.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Graves Ophthalmopathy market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Graves Ophthalmopathy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Graves Ophthalmopathy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Graves Ophthalmopathy Epidemiology, Segmented as -
-
Prevalent Cases of Graves’ Ophthalmopathy in the 7MM [2019–2032]
-
Diagnosed Prevalent Cases of Graves’ Ophthalmopathy in the 7MM [2019–2032]
-
Acute Diagnosed Prevalent Cases of Graves’ Ophthalmopathy in the 7MM [2019–2032]
-
Moderate-to-severe Drug-treated Cases of Acute Graves’ Ophthalmopathy in the 7MM [2019–2032]
-
Gender-specific Diagnosed Prevalent Cases of Graves’ Ophthalmopathy in the 7MM [2019–2032]
-
Diagnosed Prevalent Cases of Graves’ Ophthalmopathy by Chronicity in the 7MM [2019–2032]
Graves Ophthalmopathy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Graves Ophthalmopathy market or expected to be launched during the study period. The analysis covers the Graves Ophthalmopathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Graves Ophthalmopathy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Graves Ophthalmopathy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/graves-ophthalmopathy-market
Graves Ophthalmopathy Therapeutics Analysis
The dynamics of the Graves’ Ophthalmopathy market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, and incremental healthcare spending worldwide.
To improve the treatment scenario, several major pharma and biotech giants are developing therapies for Graves Ophthalmopathy. Currently, Novartis is leading the therapeutics market with its Graves Ophthalmopathy drug candidates in the most advanced stage of clinical development.
The Leading Players in the Graves Ophthalmopathy Therapeutics Market Include:
-
Argenx
-
HanAll Biopharma
-
Harbour BioMed
-
Immunovant Sciences
-
Novartis
-
Sling Therapeutics, Inc.
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
-
ValenzaBio
-
Viridian Therapeutics, Inc.
And Many Others
Graves Ophthalmopathy Emerging and Marketed Drugs Covered in the Report Include:
-
Aflibercept: Regeneron Pharmaceuticals
-
Batoclimab (HBM9161): Harbour BioMed
-
Linsitinib: Sling Therapeutics
-
Secukinumab: Novartis Pharmaceuticals
-
TEPEZZA (teprotumumab): Horizon Therapeutics
-
VB421: ValenzaBio
-
VRDN-001: Viridian Therapeutics
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/graves-ophthalmopathy-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Graves Ophthalmopathy Competitive Intelligence Analysis
4. Graves Ophthalmopathy Market Overview at a Glance
5. Graves Ophthalmopathy Disease Background and Overview
6. Graves Ophthalmopathy Patient Journey
7. Graves Ophthalmopathy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Graves Ophthalmopathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Graves Ophthalmopathy Unmet Needs
10. Key Endpoints of Graves Ophthalmopathy Treatment
11. Graves Ophthalmopathy Marketed Products
12. Graves Ophthalmopathy Emerging Drugs and Latest Therapeutic Advances
13. Graves Ophthalmopathy Seven Major Market Analysis
14. Attribute Analysis
15. Graves Ophthalmopathy Market Outlook (In US, EU5, and Japan)
16. Graves Ophthalmopathy Access and Reimbursement Overview
17. KOL Views on the Graves Ophthalmopathy Market
18. Graves Ophthalmopathy Market Drivers
19. Graves Ophthalmopathy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/graves-ophthalmopathy-market
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
